$0.32
1.56%
Downside
Day's Volatility :5.09%
Upside
3.59%
31.75%
Downside
52 Weeks Volatility :91.3%
Upside
87.25%
Period | Gamida Cell Ltd | |
---|---|---|
3 Months | -72.41% | |
6 Months | -83.84% | |
1 Year | -75.19% | |
3 Years | -96.77% |
Market Capitalization | 43.8M |
Book Value | $0.0 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.82 |
Wall Street Target Price | 4.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2680.24% |
Return On Assets TTM | -41.47% |
Return On Equity TTM | -1103.79% |
Revenue TTM | 673.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -75.9M |
Diluted Eps TTM | -0.82 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.71 |
EPS Estimate Next Year | -0.56 |
EPS Estimate Current Quarter | -0.17 |
EPS Estimate Next Quarter | -0.15 |
What analysts predicted
Upside of 1150.0%
Sell
Neutral
Buy
Gamida Cell Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Gamida Cell Ltd | -46.09% | -83.84% | -75.19% | -96.77% | -97.06% |
![]() Moderna, Inc. | 14.4% | -34.97% | -51.36% | -48.82% | 345.97% |
![]() Regeneron Pharmaceuticals, Inc. | 5.45% | 11.42% | 13.15% | 75.11% | 123.61% |
![]() Novo Nordisk A/s | -4.11% | 21.75% | 48.89% | 177.94% | 327.61% |
![]() Seagen, Inc. | 2.71% | 11.07% | 66.1% | 14.54% | 259.34% |
![]() Vertex Pharmaceuticals Incorporated | -7.59% | 2.8% | 11.45% | 56.2% | 102.13% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Gamida Cell Ltd | NA | NA | NA | -0.71 | -11.04 | -0.41 | 0.0 | 0.0 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Gamida Cell Ltd | Buy | $43.8M | -97.06% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $30.4B | 345.97% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 123.61% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 327.61% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 259.34% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 102.13% | 26.38 | 35.94% |
ARK Investment Management LLC
Marshall Wace Asset Management Ltd
Lazard Asset Management LLC
Victory Capital Management Inc.
Gamida Cell Ltd’s price-to-earnings ratio stands at None
Read Moregamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.
Organization | Gamida Cell Ltd |
Employees | 143 |
CEO | Mr. Shai Lankry CPA, M.B.A. |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$0.32
-1.84%
Advisorshares Alpha Dna Equity Sentiment Etf
$0.32
-1.84%
Falcon's Beyond Global Inc
$0.32
-1.84%
Jaguar Global Growth Corporation I
$0.32
-1.84%
Missfresh Ltd
$0.32
-1.84%
Shuaa Partners Acquisition Corp I
$0.32
-1.84%
Rose Hill Acquisition Corp
$0.32
-1.84%
Partners Bancorp
$0.32
-1.84%
Bsquare Corp
$0.32
-1.84%